TrialAlzheimer's research & therapy2016

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.

Rik Vandenberghe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.